Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer’s disease

Osamu Kano1
Yoshihisa Urita2
Hirono Ito1
Takanori Takazawa1
Yuji Kawase1
Kiyoko Murata1
Takehisa Hirayama1
Ken Miura1
Yuichi Ishikawa1
Tetsuhiyo Kiyozuka3
Jo Aoyagi3
Yasuo Iwasaki1

1Department of Neurology, 2Department of General Medicine and Emergency Care, Toho University Omori Medical Center, Tokyo, Japan; 3Department of Neurology, Federation of National Public Service Personnel Mutual Aid Associations, Mishuku Hospital, Tokyo, Japan

Objective: While acetylcholinesterase inhibitors, such as donepezil, galantamine, and rivastigmine, are beneficial in treating behavioral symptoms of patients with Alzheimer’s disease (AD), their dose-limiting effects include gastrointestinal disturbances, such as nausea, vomiting, and diarrhea. We aimed to predict the occurrence of these gastrointestinal disturbances with rivastigmine therapy for optimal drug choice and improved compliance.

Materials and methods: Thirty patients with mild-to-moderate AD (scores 10–22 on the Mini-Mental State Examination) were administered a rivastigmine 18 mg patch with domperidone 30 mg (R WD) and without domperidone (R WOD; n = 15 each) for 20 weeks. Gastrointestinal disturbances were evaluated using a frequency scale for symptoms of gastroesophageal reflux disease (FSSG), Bristol stool form scale, laboratory data (hemoglobin, albumin, total cholesterol), body weight, and amount of food intake.

Results: After 12 weeks, FSSG scores were higher in the R WOD group compared to baseline scores; however, no significant differences were noted between the R WD and R WOD groups. We then subdivided each group based on high and low baseline scores; the R WOD high-score ($\geq 4$) subgroup showed increased FSSG after 12 weeks compared with the baseline score. In both R WD and R WOD groups, the low-score ($\leq 3$) subgroups showed no changes during the dose-escalation phase.

Conclusion: For AD patients with higher FSSG scores at baseline, domperidone was effective in preventing rivastigmine-related gastrointestinal disturbances.

Keywords: Alzheimer’s disease, acetylcholinesterase inhibitors, domperidone, gastroesophageal reflux disease, gastrointestinal disturbance, rivastigmine

Introduction

Alzheimer’s disease (AD) is a progressive illness of the elderly. Patients show increasing declines in cognition, and behavioral symptoms occur in all stages of AD. While all AD patients can present with depression, agitation, and aggressive behaviors, behavioral difficulties are most pronounced in the advanced stages of the disease.1–3

Rivastigmine, inhibiting both acetylcholinesterase and butyrylcholinesterase, is the first transdermal treatment available for AD patients, and has been widely approved for the symptomatic treatment of AD.4,5 By providing continuous delivery of medication from the skin into the bloodstream, these patches achieve sustained, high drug concentration in the plasma over 24 hours.6 However, the Investigation of transDermal Exelon in ALzheimer’s disease (IDEAL) study revealed that AD patients receiving a 10 cm$^2$ patch frequently suffered from nausea (7.2%) and vomiting (6.2%).4 Further, Japanese AD patients receiving an 10 cm$^2$ patch also showed similar adverse events,
including nausea (7.0%) and vomiting (8.0%). AD patients have been reported to stop the medication because of these adverse effects; however, no technique is currently available to predict the occurrence of these adverse effects.

The antiemetic domperidone is often administered in order to administer higher, more effective dosages of cholinesterase inhibitors (ChEIs), and such a combination with domperidone has been shown to be effective in preventing rivastigmine-related gastrointestinal disturbances when administered orally in the rivastigmine capsule form. In the present study, we examined the occurrence of gastrointestinal disturbances related to the use of the rivastigmine patch using the frequency scale for the symptoms of gastroesophageal reflux disease (FSSG), Bristol stool form scale, laboratory data, body weight, and amount of food intake. In addition, we compared the differences in gastrointestinal disturbances when using a rivastigmine patch with domperidone (RWD) and without domperidone (RWOD) in order to examine the efficacy of domperidone orally.

**Materials and methods**

Patients were recruited from February 2012 to January 2013 at the Department of Neurology, Toho University Omori Medical Center, Tokyo, Japan. Subjects included outpatients diagnosed with AD who lived with or had regular daily visits from a responsible caregiver. The diagnosis of AD was based on the criteria from the National Institute of Neurological Disorders and Stroke and the Alzheimer's Association. The criteria have been established by clinical and neuropsychological examination. Cognitive impairments have to be progressive and be present in two or more areas of cognition. The onset of the deficits has been between the ages of 40 and 90 years, and finally there must be an absence of other diseases capable of producing a dementia syndrome. Patients were excluded if they were undergoing therapy with antiemetic and/or antiulcer medications. A total of 30 patients with mild-to-moderate AD (scores 10–22 on the Mini-Mental State Examination [MMSE]11) were enrolled and randomly allocated to two groups by the envelope method, ie, RWD and RWOD (n = 15 each). Dose titrations of rivastigmine patches were performed every 4 weeks using 4.5 mg/day increments from 4.5 mg/day to 18 mg/day. Domperidone was administered orally at a dose of 30 mg/day in the RWD group. Patients received rivastigmine-patch treatment for 20 weeks, and were evaluated for gastrointestinal disturbances at baseline and at weeks 4, 8, 12, 16, and 20.

The FSSG is a simplified questionnaire for evaluation of the symptoms of gastroesophageal reflux disease (GERD), and has been demonstrated to be a useful tool for objectively evaluating symptoms in GERD patients. The questionnaire consists of twelve items that are scored as 0–4 based on the frequency of the symptom (0 = never, 1 = occasionally, 2 = sometimes, 3 = often, and 4 = always) with total scores ranging from 0 to 48. The twelve questions are as follows: (1) Do you get heartburn? (2) Does your stomach get bloated? (3) Does your stomach ever feel heavy after meals? (4) Do you sometimes subconsciously rub your chest with your hand? (5) Do you ever feel sick after meals? (6) Do you get heartburn after meals? (7) Do you have an unusual (eg, burning) sensation in your throat? (8) Do you feel full while eating meals? (9) Do some things get stuck when you swallow? (10) Do you get bitter liquid (acid) coming up into your throat? (11) Do you burp a lot? (12) Do you get heartburn if you bend over?

The Bristol stool form scale consists of seven types (1, separate hard lumps, like nuts; 2, sausage-shaped but lumpy; 3, like a sausage or snake, but with cracks on its surface; 4, like a sausage or snake, smooth and soft; 5, soft blobs with clear-cut edges; 6, fluffy pieces with ragged edges, a mushy stool; and 7, watery, no solid pieces). The FSSG and Bristol stool form scale scores were obtained not only from patients but also from their caregivers to obtain accurate information. If the scores differed between the patient and his/her caregiver, we usually took the caregiver’s score, because of the patient’s cognitive impairment. In addition, we evaluated the changes in laboratory data (hemoglobin [Hb], albumin [Alb], and total cholesterol [T-Chol]), body weight, and amount of food intake to evaluate the nutritional status of AD patients. The amount of food intake per day was set as a score of 10 at baseline, and any improvement or loss in appetite was reflected as increased or decreased scores, respectively, based on patient and caregiver feedback.

Statistical analysis was performed by StatMate (Graph-Pad Software, La Jolla, CA, USA), with the Mann–Whitney U test and Wilcoxon signed-rank test, with P < 0.05 used as the threshold for statistical significance. This study was approved by the Ethical Committee of Toho University Omori Medical Center. All patients and legally accepted caregivers participating in the trial were given an explanation of the trial by the investigators before the start of study, and informed consent to participate in the study was obtained. Consent of patients was obtained orally or in writing, and
the consent of legally accepted representatives was always obtained in writing.

Results

Patient characteristics

We enrolled and screened 30 patients in this study. Overall, three patients from the RWD group discontinued their participation due to skin irritation, and one patient from the RWOD group withdrew because of nausea. The patient demographic data are shown in Table 1. No differences were observed between the RWD and RWOD groups with respect to mean age, the sex ratio, MMSE score, or body weight.

Changes during the dose-escalation phase

The FSSG scores for the RWOD group showed significant increases after 12 weeks compared with baseline (versus 12 weeks, P = 0.035; versus 16 weeks, P = 0.034; versus 20 weeks, P = 0.034); however, this was not observed in the RWD group (Figure 1). Before initiating rivastigmine-patch therapy, 23 of 30 patients (RWD group, eleven of 15; RWOD group, twelve of 15 patients) showed the presence of some gastrointestinal symptoms based on the FSSG questionnaire. Therefore, we divided each group into two subgroups based on the baseline scores. The median value of the FSSG at baseline was 3.8 in the RWD group and 3.1 in the RWOD group; therefore, we set the high-score threshold $\geq$4 points and low-score threshold $\leq$3 points. In the RWOD group, the high-score subgroup showed increased FSSG scores after 12 weeks compared with baseline scores (versus 12 weeks, P = 0.038; versus 16 weeks, P = 0.035; versus 20 weeks, P = 0.034); however, no such changes were observed in the high-score subgroup in the RWD group (Figure 2). In both RWD and RWOD groups, the low-score subgroups showed no changes in FSSG scores during the dose-escalation phase. The data for MMSE, laboratory results (Hb, Alb, and T-Chol), body weight, amount of food intake, and Bristol stool form scale scores are shown in Table 2; no differences were noted between the baseline values and those at week 20 for either group.

Comparison between RWD and RWOD groups

We compared the data for the RWD and RWOD groups for all the parameters examined. No significant differences were observed between the two groups for the FSSG (Figure 1), MMSE, laboratory data, body weight, amount of food intake, or Bristol stool form scale scores (Table 2).

Discussion

Vomiting is a highly specific physical event, defined as “the rapid, forceful evacuation of gastric contents in retrograde fashion from the stomach up to and out of the mouth.” In contrast, nausea is an entirely subjective experience, defined as “the sensation that immediately precedes vomiting,” wherein patients feel that they are about to vomit. Rivastigmine patch-related gastrointestinal disturbances have been reported in less than 10% of patients receiving this therapy.\(^4,5\) In our study, only one patient from the RWOD group discontinued the therapy due to nausea. However, our FSSG questionnaire findings revealed that 23 of 30 AD patients (>75%) suffered from at least one gastrointestinal disturbance before the initiation of the rivastigmine patch. Furthermore, AD patients with higher FSSG were observed to show a further increase in the FSSG score during the dose-escalation phase. Our results may indicate that AD patients do not report gastrointestinal disturbances because of the memory deficits involved in AD.
Domperidone, a dopamine antagonist that acts by blocking dopamine receptors in the chemoreceptor trigger zone, has been previously shown to prevent gastrointestinal disturbances in rivastigmine therapy administered orally.\(^7\) In the present study, domperidone was effective in reducing or preventing gastrointestinal disturbances during the dose-escalation phase of rivastigmine-patch therapy in AD patients with higher FSSG scores at baseline.

The FSSG is a convenient tool for evaluating the symptoms of GERD; in our experience, patients/caregivers require approximately 1 minute to complete the questionnaire. The questionnaire consists of twelve detailed items; therefore, the slightest gastrointestinal problem can be easily detected. In order to obtain accurate information in the present study, we confirmed the symptoms described by the AD patients using FSSG questionnaires completed by their caregivers.

At present, there is no technique for predicting the occurrence of gastrointestinal disturbances with rivastigmine-patch therapy. It has been suggested that pretreatment with domperidone may protect against the onset of centrally induced nausea and vomiting induced by ChEIs.\(^12\) However, our findings indicate that AD patients with low FSSG scores at baseline may not require additional antiemetic and/or antiulcer medications. On the other hand, AD patients with initial high FSSG scores showed elevations in the FSSG scores during the dose-escalation phase, indicating an increased frequency of gastrointestinal disturbances. Therefore, clinicians should pay careful attention to AD patients with high FSSG scores at baseline during the dose-escalation phase to prevent gastrointestinal disturbances and to avoid patient discontinuation of rivastigmine-patch therapy. Domperidone has, on rare occasions, been associated with acute extrapyramidal syndromes;\(^13\) however, our AD patients did not show such side effects.

Randomized, double-blind clinical trials conducted with other ChEIs, such as donepezil and galantamine, have provided evidence that these are safe and effective therapies against cognitive dysfunction and behavioral symptoms.\(^14\)\(^-\)\(^16\) However, similar to the side effects of rivastigmine-patch therapy, gastrointestinal disturbances are the primary adverse effects associated with this therapy. We speculate that the FSSG may be a useful tool for predicting and preventing ChEI-related gastrointestinal disturbances for these drugs.

### Table 2 Comparison between the RWD and RWOD groups at baseline and week 20

|                     | RWD at baseline | RWD at 20 weeks | RWOD at baseline | RWOD at 20 weeks | P-value at baseline |
|---------------------|-----------------|-----------------|------------------|------------------|---------------------|
| MMSE, mean (SD)     | 16.9 (3.0)      | 17.7 (5.0)      | 16.2 (4.0)       | 17.9 (4.7)       | 0.604               |
| Laboratory data     |                 |                 |                  |                  |                     |
| Hb (mg/dL), mean (SD)| 13.8 (0.6)     | 13.8 (0.5)      | 13.9 (0.7)       | 13.9 (0.7)       | 0.365               |
| Alb (mg/dL), mean (SD)| 4.3 (0.29)     | 4.3 (0.31)      | 4.3 (0.35)       | 4.2 (0.40)       | 0.640               |
| T-Chol (mg/dL), mean (SD)| 216 (19.1)   | 211 (18.5)      | 212 (15.1)       | 210 (18.1)       | 0.662               |
| Body weight (kg), mean (SD)| 53.5 (9.82) | 53.3 (9.73)      | 55.1 (7.38)      | 55.8 (8.11)      | 0.698               |
| Amount of food intake| 10             | 9.8 (0.32)      | 10               | 9.9 (0.2)        | 0.977               |
| Bristol stool form scale mean (SD)| 3.5 (0.87) | 3.2 (0.92)      | 3.4 (0.5)        | 3.3 (0.63)       |                     |

**Abbreviations:** RWD, rivastigmine patch with domperidone; RWOD, rivastigmine patch without domperidone; MMSE, Mini-Mental State Examination; Hb, hemoglobin; Alb, albumin; T-Chol, total cholesterol; SD, standard deviation.
The results of this study must be viewed in light of its limitations. This study did not include a placebo for domperidone, and was limited by the small sample size; therefore, improvements in cognitive dysfunction with rivastigmine-patch therapy could not be demonstrated fully. Further studies are needed to confirm our findings.

It is important to optimize the drug for AD in individuals to slow the rate of cognitive dysfunction and behavioral and psychological symptoms of dementia. Of note, behavior symptoms in patients with AD increase direct costs of care. For example, a 1-point increase in the Neuropsychiatric Inventory score was calculated to be equivalent to an increased cost of $247–$409 in total annual direct costs.

In addition, compared with those who never used cognitive enhancers, patients who used ChEIs had a significant delay in nursing home admission.

Conclusion

In summary, the group receiving rivastigmine-patch therapy without domperidone showed significant increases in the FSSG score after 12 weeks (dose-escalation phase) compared with baseline scores. Domperidone was effective in preventing rivastigmine-patch-related gastrointestinal disturbances in AD patients with higher FSSG scores at baseline. Further, the FSSG questionnaire may be a useful tool for the prediction of gastrointestinal symptoms associated with rivastigmine-patch therapy.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer’s disease: a natural history study. J Am Geriatr Soc. 1996;44(9):1078–1081.
2. Lopez OL, Becker JT, Sweet RA, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 2003;15(3):346–353.
3. Kano O, Ito H, Takazawa T, et al. Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil. Neuropsychiatr Dis Treat. 2013;9:259–265.
4. Winblad B, Grossberg G, Frölich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007;69(4 Suppl 1):S14–S22.
5. Nakamura Y, Imai Y, Shigeta M, et al. A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer’s disease. Dement Geriatr Cogn Dis Extra. 2011;11(1):163–179.
6. Ceve G. Drug delivery across the skin. Expert Opin Investig Drugs. 1997;6(12):1887–1937.
7. Scarzella L, Costanza A, Vastola K. Domperidone is effective in the prevention of rivastigmine-related gastrointestinal disturbances. Funct Neurol. 2007;22(2):101–104.
8. Kusano M, Shimoyama Y, Sugimoto S, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004;39(9):885–891.
9. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920–924.
10. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939–944.
11. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198.
12. Chang Yoon MC, Hartnett M, Yen M. Domperidone, a new dopamine antagonist. CMAJ. 1986;135(5):457–461.
13. Reddymasu SC, Suyokan I, McCullum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102(9):2036–2045.
14. Rogers SL, Dooey RS, Mols RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998;158(9):1021–1031.
15. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000;54(12):2261–2268.
16. Winblad B. Maintaining functional and behavioral abilities in Alzheimer disease. Alzheimer Dis Assoc Disord. 2001;15 Suppl 1:S34–S40.
17. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–324.
18. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366(10):893–903.
19. Cummings JL, Schneider E, Tariot PN, Graham SM. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006;67(1):57–63.
20. Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer’s disease. Drugs Aging. 2003;20(10):777–789.
21. Cummings JL. The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):S10–S16.
22. Murman DL, Chen Q, Powell MC, Kuo SB, Bradley CJ, Colenda CC. The incremental direct costs associated with behavioral symptoms in AD. Neurology. 2002;59(11):1721–1729.
23. Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the comitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(6):600–607.